ACE2 X-Ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis

The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral membrane protein of 805 amino acids that contains one HEXXH + E zinc-binding consensus sequence. ACE2 has been implicated in the regulation of heart function and also as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). To gain further insights into this enzyme, the first crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains were solved to 2.2- and 3.0-Å resolution, respectively. Comparison of these structures revealed a large inhibitor-dependent hinge-bending movement of one catalytic subdomain relative to the other (∼16°) that brings important residues into position for catalysis. The potent inhibitor MLN-4760 ((S,S)-2-{1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol4-yl]-ethylamino}-4-methylpentanoic acid) makes key binding interactions within the active site and offers insights regarding the action of residues involved in catalysis and substrate specificity. A few active site residue substitutions in ACE2 relative to ACE appear to eliminate the S2′ substrate-binding subsite and account for the observed reactivity change from the peptidyl dipeptidase activity of ACE to the carboxypeptidase activity of ACE2.

[1]  R. Shapiro,et al.  Inhibition of angiotensin converting enzyme: dependence on chloride. , 1984, Biochemistry.

[2]  G Bricogne,et al.  Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. , 2003, Acta crystallographica. Section D, Biological crystallography.

[3]  Jodie L. Guy,et al.  Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. , 2003, Biochemistry.

[4]  D. Rodgers,et al.  Structure of neurolysin reveals a deep channel that limits substrate access , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. McRee Practical Protein Crystallography , 1993 .

[6]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[7]  M. Capecchi,et al.  Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[8]  J. Charles Jennette,et al.  Male–female differences in fertility and blood pressure in ACE-deficient mice , 1995, Nature.

[9]  Hai-yan Wang,et al.  Collectrin, a Collecting Duct-specific Transmembrane Glycoprotein, Is a Novel Homolog of ACE2 and Is Developmentally Regulated in Embryonic Kidneys* , 2001, The Journal of Biological Chemistry.

[10]  R. Natesh,et al.  Crystal structure of the human angiotensin-converting enzyme–lisinopril complex , 2003, Nature.

[11]  M. Gerstein,et al.  A database of macromolecular motions. , 1998, Nucleic acids research.

[12]  W. Bode,et al.  Structure of astacin with a transition-state analogue inhibitor , 1996, Nature Structural Biology.

[13]  J. Knowles,et al.  To build an enzyme.... , 1991, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[14]  D. R. Holland,et al.  Structural comparison suggests that thermolysin and related neutral proteases undergo hinge-bending motion during catalysis. , 1992, Biochemistry.

[15]  N. Rawlings,et al.  Evolutionary families of metallopeptidases. , 1995, Methods in enzymology.

[16]  J F Riordan,et al.  Anion activation of angiotensin converting enzyme: dependence on nature of substrate. , 1983, Biochemistry.

[17]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[18]  N. Hooper,et al.  The angiotensin-converting enzyme gene family: genomics and pharmacology. , 2002, Trends in pharmacological sciences.

[19]  B. Hao,et al.  Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. , 2002, Structure.

[20]  J. Thompson,et al.  Using CLUSTAL for multiple sequence alignments. , 1996, Methods in enzymology.

[21]  M. A. Wouters,et al.  Angiotensin I-converting Enzyme Transition State Stabilization by His1089 , 2001, The Journal of Biological Chemistry.

[22]  J. Kraut,et al.  How do enzymes work? , 1988, Science.

[23]  J F Riordan,et al.  Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H M Holden,et al.  Slow- and fast-binding inhibitors of thermolysin display different modes of binding: crystallographic analysis of extended phosphonamidate transition-state analogues. , 1989, Biochemistry.

[25]  J. Inman,et al.  A deeply recessed active site in angiotensin-converting enzyme is indicated from the binding characteristics of biotin-spacer-inhibitor reagents. , 1990, Biochemical and biophysical research communications.

[26]  M. Crackower,et al.  The role of ACE2 in cardiovascular physiology. , 2003, Trends in cardiovascular medicine.

[27]  Wolfgang Baumeister,et al.  A giant protease with a twist: the TPP II complex from Drosophila studied by electron microscopy , 2002, The EMBO journal.

[28]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[29]  Affinity chromatographic purification of angiotensin converting enzyme. , 1984, Biochemistry.

[30]  S. Teague Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[31]  Ook Joon Yoo,et al.  Crystal structure of Drosophila angiotensin I‐converting enzyme bound to captopril and lisinopril 1 , 2003, FEBS letters.

[32]  P Corvol,et al.  Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Dimitrov,et al.  The SARS-CoV S glycoprotein: expression and functional characterization , 2003, Biochemical and Biophysical Research Communications.

[34]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[35]  P. Argos,et al.  Knowledge‐based protein secondary structure assignment , 1995, Proteins.

[36]  D. Tillman,et al.  Monoclonal anti-DNA antibodies: structure, specificity, and biology. , 1997, Methods.

[37]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[38]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[39]  James M. Gavin,et al.  Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. , 2002, Journal of the American Chemical Society.

[40]  U. Eriksson,et al.  A story of two ACEs , 2003, Journal of Molecular Medicine.

[41]  A. Lesk,et al.  Structural mechanisms for domain movements in proteins. , 1994, Biochemistry.

[42]  M. A. Wouters,et al.  Arg1098 Is Critical for the Chloride Dependence of Human Angiotensin I-converting Enzyme C-domain Catalytic Activity* , 2001, The Journal of Biological Chemistry.

[43]  R. Natesh,et al.  Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. , 2003, The Biochemical journal.

[44]  C. A. Stone,et al.  A new class of angiotensin-converting enzyme inhibitors , 1980, Nature.

[45]  László Polgár,et al.  Prolyl Oligopeptidase An Unusual β-Propeller Domain Regulates Proteolysis , 1998, Cell.

[46]  J P Abrahams,et al.  New developments in phase refinement. , 1998, Current opinion in structural biology.

[47]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[48]  Jorge Navaza,et al.  [33] AMoRe: An automated molecular replacement program package. , 1997, Methods in enzymology.

[49]  Brian W. Matthews,et al.  Structural basis of the action of thermolysin and related zinc peptidases , 1988 .

[50]  P. R. David,et al.  5 – PROTEIN CRYSTALLOGRAPHY COOKBOOK , 1999 .

[51]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.